Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Clin North Am. 2004 May;31(2):219-26.

Screening for prostate cancer: current recommendations.

Author information

  • 1Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA. shandra.wilson@uchsc.edu

Abstract

Recent studies have questioned the efficacy of PSA as a marker for the early detection of prostate cancer, but techniques are being investigated to improve the sensitivity and specificity of screening. It is hoped that new methods can differentiate between lethal and nonlethal cancers, thereby avoiding lead-time bias. Even with the current limitations of PSA, the combination of stage migration seen with screening, the recent Scandinavian study showing decrease of disease progression following surgical extirpation, and the known mortality in patients presenting with advanced disease help support PSA screening for prostate cancer. It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening.

PMID:
15123402
DOI:
10.1016/j.ucl.2004.01.002
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center